Economics of Treatments for Non-Small Cell Lung Cancer
| Autor: | Christos Chouaid, Alain Vergnenegre, Kukovi Atsou, Gilles Hejblum |
|---|---|
| Přispěvatelé: | Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Pathologie respiratoire et allergologie [CHU Limoges], CHU Limoges, C Chouaid, K Atsou, G Hejblum, SCHILLER A, Pôle de Pharmacie - Santé Publique - Information médicale [Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC) |
| Rok vydání: | 2009 |
| Předmět: |
Oncology
MESH: Combined Modality Therapy Lung Neoplasms Cost effectiveness Cost-Benefit Analysis MESH: Taxoids Docetaxel 0302 clinical medicine Glutamates Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Medicine 030212 general & internal medicine health care economics and organizations Health Policy Combined Modality Therapy 3. Good health MESH: Antineoplastic Combined Chemotherapy Protocols MESH: Quinazolines Pemetrexed 030220 oncology & carcinogenesis Taxoids Erlotinib medicine.drug medicine.medical_specialty Guanine Erlotinib Hydrochloride 03 medical and health sciences MESH: Glutamates Internal medicine Humans Lung cancer MESH: Guanine Pharmacology MESH: Humans Performance status business.industry Public Health Environmental and Occupational Health Cancer medicine.disease MESH: Lung Neoplasms respiratory tract diseases Surgery Localized disease Quinazolines [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie business MESH: Carcinoma Non-Small-Cell Lung MESH: Cost-Benefit Analysis |
| Zdroj: | PharmacoEconomics PharmacoEconomics, 2009, 27 (2), pp.113-25 PharmacoEconomics, Springer Verlag, 2009, 27 (2), pp.113-25 ResearcherID |
| ISSN: | 1170-7690 |
| Popis: | International audience; The purpose of this article is to review the economics of treatments for non-small cell lung cancer (NSCLC). We systematically analysed the cost effectiveness of treatments for the different stages of NSCLC, with particular emphasis on more recently approved agents. Numerous economic analyses in NSCLC have been conducted, with a variety of methods and in a number of countries. In patients with localized disease, adjuvant chemotherapy appears to have greater cost effectiveness than observation; however, there are few published data. In locally advanced disease, combined modalities (chemotherapy, surgery and/or radiotherapy) are probably cost effective, but high-quality economic analyses are lacking. In advanced NSCLC, third-generation chemotherapies used in the first-line setting can be administered with acceptable incremental cost effectiveness. In the second-line setting, new agents (docetaxel, pemetrexed and erlotinib) have acceptable cost effectiveness. The lack of cost-utility analyses for elderly patients and patients with a poor prognosis rules out firm conclusions. This review suggests that most therapies for NSCLC are cost effective when the patient has a good performance status, with an incremental cost-effectiveness ratio under USD 50,000 per life-year gained in the majority of cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink